- After a median follow-up of 16 months, the complete
ablation rate in Luminal A and B breast cancer tumors ≤ 25mm
was 100%
- Study concluded that most non-surgical patients with
early-stage breast cancer accepted cryoablation when the treatment
was offered and that cryoablation is a safe, effective alternative
to surgery and well-tolerated as an out-patient
procedure
CAESAREA, Israel, Aug. 14,
2024 /PRNewswire/ -- IceCure Medical
Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the
"Company"), developer of minimally-invasive cryoablation technology
that destroys tumors by freezing as an alternative to surgical
tumor removal, today announced the publication of an independent
study titled "Acceptance and results of cryoablation for the
treatment of early breast cancer in non-surgical patients" in the
British Journal of Radiology, a publication of the British
Institute of Radiology. The single-site study, led by Lucia L. Garna Lopez, PhD, was conducted by
researchers in the radiology, oncology, and surgery departments at
Hospital Lucus Augusti in Lugo, Spain.
![IceCure Medical Logo IceCure Medical Logo](https://mma.prnewswire.com/media/2319310/IceCure_Medical_Logo.jpg)
The aim of the study was to evaluate the acceptance of
percutaneous cryoablation treatment by patients with early-stage
breast cancer who choose not to have surgery. Of the 45 patients
offered cryoablation with ProSense®, 43 patients, or 95.6%
accepted. 36 of these, representing 39 malignant tumors (median
size 24mm), proceeded to undergo cryoablation.
"This study is a good case in point that when women who elect
not to have surgery, or are not eligible for surgery, are given the
option, they overwhelmingly choose cryoablation to treat their
breast cancer," stated IceCure CEO Eyal
Shamir. "In addition to providing excellent data on the
safety and efficacy of ProSense® in patients who chose not undergo
surgery, the study's authors also point to the correlation between
a larger aging population, increased risk of breast cancer with
age, and the fact that most patients who elect not to have surgery
or are not eligible are elderly patients. These factors, we
believe, point to increasing demand for ProSense® when it is
presented as an option."
The median age of patients treated with cryoablation was 87,
with a range of 60-96. After a median follow-up of 16 months, the
complete ablation rate in luminal breast cancer with tumors ≤ 25mm
was 100%. No major complications were seen.
The study investigators concluded that most non-surgical
patients with early-stage breast cancer accepted cryoablation when
the treatment was offered and that cryoablation is safe, effective,
and well-tolerated as an outpatient procedure. The published
article went on to state that outcomes suggest cryoablation could
be an alternative to surgery for the management of breast cancer in
this group of patients and pointed to financial, physical, and
cosmetic benefits.
About ProSense®
The
ProSense® Cryoablation System provides a
minimally invasive treatment option to destroy tumors by freezing
them. The system uniquely harnesses the power of liquid nitrogen to
create large lethal zones for maximum efficacy in tumor destruction
in benign and cancerous lesions, including breast, kidney, lung,
and liver.
ProSense® enhances patient and provider value by accelerating
recovery, reducing pain, surgical risks, and complications. With
its easy, transportable design and liquid nitrogen utilization,
ProSense® opens that door to fast and convenient office-based
procedure for breast tumors.
About IceCure Medical
IceCure Medical
(Nasdaq: ICCM) develops and markets
advanced liquid-nitrogen-based cryoablation therapy
systems for the treatment of tumors (benign and cancerous) by
freezing, with the primary focus areas being breast, kidney, bone
and lung cancer. Its minimally invasive technology is a safe and
effective alternative to hospital surgical tumor removal that is
easily performed in a relatively short procedure. The Company's
flagship ProSense® system is marketed and sold
worldwide for the indications cleared and approved to date
including in the U.S., Europe and China.
Forward Looking Statements
This press release
contains forward-looking statements within the meaning of the "safe
harbor" provisions of the Private Securities Litigation Reform Act
of 1995 and other Federal securities laws. Words such as "expects,"
"anticipates," "intends," "plans," "believes," "seeks," "estimates"
and similar expressions or variations of such words are intended to
identify forward-looking statements. For example, IceCure
is using forward looking statements in this press release
when it discusses the belief that the correlation between an aging
population, increased risk of breast cancer with age, and the fact
that most patients who elect not to have surgery or are not
eligible are elderly patients point to increasing demand for
ProSense® when it is presented as an option. Historical
results of scientific research and clinical and preclinical trials
do not guarantee that the conclusions of future research or trials
will suggest identical or even similar conclusions. Important
factors that could cause actual results, developments and business
decisions to differ materially from those anticipated in these
forward-looking statements include, among others: the Company's
planned level of revenues and capital expenditures; the Company's
available cash and its ability to obtain additional funding; the
Company's ability to market and sell its products; legal and
regulatory developments in the United
States and other countries; the Company's ability to
maintain its relationships with suppliers, distributors and other
partners; the Company's ability to maintain or protect the validity
of its patents and other intellectual property; the Company's
ability to expose and educate medical professionals about its
products; political, economic and military instability in the
Middle East, specifically in
Israel; as well as those factors
set forth in the Risk Factors section of the Company's Annual
Report on Form 20-F for the year ended December 31, 2023 filed with the SEC on
April 3, 2024, and other documents
filed with or furnished to the SEC which are available on the SEC's
website, www.sec.gov. The Company undertakes no
obligation to update these statements for revisions or changes
after the date of this release, except as required by
law
IR Contact:
Email:
investors@icecure-medical.com
Michael Polyviou
Phone: 732-232-6914
Todd Kehrli
Phone: 310-625-4462
Logo -
https://mma.prnewswire.com/media/2319310/IceCure_Medical_Logo.jpg
View original
content:https://www.prnewswire.com/news-releases/icecures-prosense-destroyed-100-of-breast-cancer-tumors-in-independent-study-of-patients-who-chose-cryoablation-instead-of-surgery-302222148.html
SOURCE IceCure Medical